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Coreceptor affinity for MHC defines peptide
specificity requirements for TCR interaction
with coagonist peptide–MHC
John A.H. Hoerter,1 Joanna Brzostek,1 Maxim N. Artyomov,7
Steven M. Abel,3,4,5 Javier Casas,1 Vasily Rybakin,1 Jeanette Ampudia,1
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Recent work has demonstrated that nonstimulatory endogenous peptides can enhance T cell
recognition of antigen, but MHCI- and MHCII-restricted systems have generated very different results. MHCII-restricted TCRs need to interact with the nonstimulatory peptide–MHC
(pMHC), showing peptide specificity for activation enhancers or coagonists. In contrast, the
MHCI-restricted cells studied to date show no such peptide specificity for coagonists, suggesting that CD8 binding to noncognate MHCI is more important. Here we show how this
dichotomy can be resolved by varying CD8 and TCR binding to agonist and coagonists coupled
with computer simulations, and we identify two distinct mechanisms by which CD8 influences
the peptide specificity of coagonism. Mechanism 1 identifies the requirement of CD8 binding
to noncognate ligand and suggests a direct relationship between the magnitude of coagonism
and CD8 affinity for coagonist pMHCI. Mechanism 2 describes how the affinity of CD8 for
agonist pMHCI changes the requirement for specific coagonist peptides. MHCs that bind CD8
strongly were tolerant of all or most peptides as coagonists, but weaker CD8-binding MHCs
required stronger TCR binding to coagonist, limiting the potential coagonist peptides. These
findings in MHCI systems also explain peptide-specific coagonism in MHCII-restricted cells, as
CD4–MHCII interaction is generally weaker than CD8–MHCI.
CORRESPONDENCE
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Abbreviations used: CHO,
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The vast majority of the peptides presented by
MHC molecules are derived from self-proteins
and do not activate mature T cells. Antigen
recognition and T cell activation must thus be
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tuned to allow for recognition of the small
minority of disease-associated peptide–MHC
(pMHC) “needles in the haystack” of nonstimulatory endogenous pMHC (Davis et al., 2007;
Gascoigne, 2008; Gascoigne et al., 2010). Several experiments have shown that T cell activation by small amounts of antigen is enhanced
by the presence of endogenous peptides (Irvine
et al., 2002; Yachi et al., 2005). Although this
activation enhancement or coagonist phenomenon has been reported for both MHC class I
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(MHCI)–restricted T cells and thymocytes (Yachi et al., 2005,
2007;Anikeeva et al., 2006; Juang et al., 2010) and for MHCIIrestricted T cells (Irvine et al., 2002; Li et al., 2004; Krogsgaard
et al., 2005), the relative importance of TCR recognition of
the endogenous pMHC appears to be very different for
CD4 and CD8 T cells (Davis et al., 2007; Gascoigne, 2008;
Gascoigne et al., 2010).
The number of potential coagonist peptides for a given
CD4 T cell are very limited (Krogsgaard et al., 2005; Ebert
et al., 2009; Lo et al., 2009), whereas coagonism for CD8 T cells
or thymocytes occurs with a wide range of different nonstimulatory peptides (Yachi et al., 2005, 2007; Juang et al.,
2010).This evidence thus suggests that MHCII-restricted TCRs
discriminate between endogenous peptides, whereas MHCIrestricted TCRs do not. However, recent data indicate that
nonstimulatory pMHCI ligands show a very weak but possibly
biologically significant interaction with TCR (Juang et al.,
2010).This suggested that TCRs might play a role in coagonism
in MHCI-restricted cells but that its specificity is only evident
for very weakly stimulatory TCR ligands such as those involved in positive selection.
The CD8 coreceptor’s interaction with nonstimulatory
MHCI has been suggested to be important for coagonism in
MHCI-restricted cells (Yachi et al., 2005; Gascoigne, 2008;
Gascoigne et al., 2010). Nonstimulatory pMHC alone can
recruit CD8 to the T cell–APC interface (Yachi et al., 2005;
Rybakin et al., 2011). Also, coagonist pMHCs became antagonists in CD8-negative cells (Stone et al., 2011).These results,
along with the lack of peptide specificity for coagonists, suggest that non-cognate CD8 coreceptor binding to nonstimulatory pMHC is the dominant mechanism of activation
enhancement for MHCI-restricted T cells. In addition, CD8
affinity for the MHC presenting the antigenic peptide (agonist) plays a direct role in signaling through the TCR, where
increasing the affinity of CD8 can increase ligand potency
and even bypass peptide specificity requirements altogether
(Laugel et al., 2007; Wooldridge et al., 2007, 2010). Because
there is a range of affinities for CD8 binding to different
MHCI molecules (Cole et al., 2012), the relative requirements for CD8, or for TCR interaction with the nonstimulatory ligand, might be expected to vary with the strength of
CD8–MHC binding. Interestingly, the two mouse MHCIrestricted TCR models that have been analyzed in coagonism experiments (OT-I [Yachi et al., 2005, 2007; Juang
et al., 2010] and 2C [Stone et al., 2011]) recognize H-2Kb or Ld,
which show relatively high-affinity CD8 binding (Cole
et al., 2012).
A stochastic, computational model has been used to investigate the role of coreceptors in TCR triggering, and results
suggest that CD8 plays a dual role of stabilizing the TCR–
pMHC interaction and of delivering the CD8-associated
kinase Lck to the TCR to initiate signaling, with the latter effect being the more important (Artyomov et al., 2010). This
model explicitly combined two key features, membrane-protein
mobility and protein–protein interactions (Lis et al., 2009), which
allowed incorporation of many biophysical measurements for
1808

MHC, TCR, and coreceptor interactions. Here, an extension
of this model allows us to describe coagonism enabled by selfpeptides, taking into account the distinct activation states of
Lck (Nika et al., 2010; Stirnweiss et al., 2013).
Because of the glaring discrepancies in the requirements
for TCR discrimination between coagonist peptides in MHCIand MHCII-restricted systems, there is a need for a unifying
concept to explain activation enhancement for both T cell
lineages. In this paper, we used H-2Kb and H-2Db single
chain (sc)–pMHCs (Yu et al., 2002; Choudhuri et al., 2005;
Palmowski et al., 2009), which allowed us to dissect the distinct contributions of CD8 affinity and of TCR affinity for
both antigenic and nonstimulatory pMHCs. Using H-2Kb–
and H-2Db–restricted TCRs and stochastic computer simulations of the kinetics of T cell activation, we describe two
distinct mechanisms by which CD8 affinity for pMHC can
influence the requirements for coagonists. Mechanism 1 describes CD8 binding to nonstimulatory pMHC as an absolute
requirement for coagonism and shows that higher-affinity
CD8–pMHC interactions can mitigate peptide specificity requirements for coagonists and increase the magnitude of enhancement. Mechanism 2 describes how the affinity of CD8
for agonist pMHC influences the requirements for TCR interaction with coagonist pMHC. A relatively simple kinetic
model of T cell activation is sufficient to account for all coagonist phenomena, thus unifying disparate observations from
CD4 and CD8 T cells.

RESULTS
Development of inducible, antigenic, sc-MHC
Chinese hamster ovary (CHO) cell expression systems
sc-pMHCI molecules are produced by recombinant constructs in which the MHC-binding peptide is linked to the
N terminus of B2-microglobulin, which in turn is linked to
the N terminus of the MHCI heavy chain (Yu et al., 2002;
Choudhuri et al., 2005; Palmowski et al., 2009). When expressed on the cell surface, these sc-MHCI constructs are very
stable and can act as potent agonists for T cells. sc-KbOVA
(OVA peptide 257–264, SIINFEKL, on H-2Kb, recognized
by OT-I TCR; Hogquist et al., 1994) and sc-DbNP68 (influenza A/NT/60/68 nucleoprotein 366–374, ASNENMDAM,
on H-2Db, recognized by F5 TCR; Townsend et al., 1986;
Mamalaki et al., 1992) in doxycycline-inducible vectors were
transfected into CHO Trex cells (expressing tetracycline repressor). Doxycycline strongly up-regulated cell surface expression of sc-MHCI, allowing the CHO cells to stimulate
antigen-specific T cell activation, as measured by CD69 upregulation or TCR endocytosis (Fig. 1). In the repressed state
(absence of doxycycline), “leaky” expression of sc-KbOVA or
sc-DbNP68 presented enough agonist to the CD8 OT-I or
F5 T cells to induce some CD69 up-regulation but not
enough to induce significant TCR down-regulation (Fig. 1,
B and D). Expression of sc-KbOVA in the repressed state was
virtually undetectable by flow cytometry with a KbOVA-specific
antibody (Fig. 1 A; and not depicted; Porgador et al., 1997),
Coagonism and the role of CD8 affinity | Hoerter et al.
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Figure 1. Expression of inducible sc-MHCI
agonist molecules KbOVA and DbNP68 in
CHO cells and activation of corresponding
OT-I and F5 CD8 T cells. (A) Trex CHO cells
expressing dox-inducible sc-MHC were stained
with anti-Kb and analyzed by flow cytometry.
Gray shading: untransfected Trex CHO cells.
Purple: repressed (no dox) sc-KbOVA. Green:
induced (+dox) sc-KbOVA. (B) OT-I T cells were
incubated with the indicated CHO cell APCs for
3 h, and TCR endocytosis (anti-VA2; left) and
CD69 expression (right) were assessed by flow
cytometry. The horizontal black line indicates
the CD69hi gate. The color coding is the same
as in A. (C and D) As in A and B except CHO
cells expressing dox-inducible sc-DbNP68
were stained with anti-Db or exposed to F5
responder T cells. TCR staining was by antiCD3d. Data are representative of three independent experiments.

whereas repressed sc-DbNP68 was detectable above background (Fig. 1 C).
Both H-2Kb and H-2Db nonstimulatory pMHCs
can be coagonists
CHO cells expressing inducible sc-KbOVA or sc-DbNP68
were super-transfected with nonstimulatory sc-MHCI constructs, enabling coexpression of agonist and nonstimulatory
pMHC on the same cell (Fig. 2). This allowed us to probe coagonism by nonstimulatory peptides presented on H-2Kb and
H-2Db, with both H-2Kb– and H-2Db–restricted TCRs.
KbVSV (RGYVYQGL) and DbUTY (WMHHNMDLI) are
nonstimulatory pMHCs for both OT-I and F5 T cells. We
found that sc-KbVSV provided strong coagonism for both
OT-I and F5 T cells, measured as CD69 up-regulation or IL2
secretion (Fig. 2, B–D and F–H, respectively), or by phosphorylation of the NF-KB precursor p-p105 (not depicted).
sc-DbUTY also provided activation enhancement for both
TCR transgenic T cells, but this was much weaker than the
sc-KbVSV effect and did not show statistically significant coagonism of IL2 secretion. Nonstimulatory sc-DbNP68 also
gave weak coagonism for OT-I T cells (not depicted). Analogous activation results were obtained with preselection OT-I
thymocytes stimulated with KbOVA-expressing CHO cells
(not depicted). These data demonstrate that both H-2Kb
and H-2Db nonstimulatory pMHC molecules were capable
of being coagonists for TCRs restricted by the same or another MHCI, but H-2Kb provided much stronger coagonism
than H-2Db.
CD8 binding to nonstimulatory pMHC is directly
related to the magnitude of coagonism
The lack of peptide specificity in coagonism in MHCIrestricted T cells could be the result of noncognate CD8 interaction with nonstimulatory MHCI molecules (Yachi et al., 2005;
JEM Vol. 210, No. 9

Anikeeva et al., 2006; Gascoigne, 2008).To test this hypothesis,
we generated D227K-E229K mutations, which are known to
abrogate CD8 binding (Connolly et al., 1988, 1990; Potter et al.,
1989), in the sc-KbVSV and sc-DbUTY A3 domains. When
super-transfected into inducible KbOVA-expressing cells
(Fig. 3 A), we found that the sc-KbVSV CD8-binding mutant
(sc-KbVSV-CD8m) did not provide coagonism to OT-I T cells
(Fig. 3 B) or preselection thymocytes (not depicted). Similarly, sc-DbUTY-CD8m expressed with repressed sc-DbNP68
did not provide coagonism for F5 cells (Fig. 3, C and D). Unexpectedly, the sc-DbUTY-CD8m had a mild and statistically
significant inhibitory effect on F5 activation. These results revealed that the intact CD8-binding site is absolutely required
for coagonism in both OT-I and F5 systems.
We also tested the ability of known H-2Kb–binding peptides (Santori et al., 2002; Yachi et al., 2005) to act as coagonists for F5 T cells.We used RMA-S cells as APCs, as these cells
express very few MHCI molecules unless exogenous peptide
is provided (Ljunggren et al., 1990; Yachi et al., 2005, 2007).
When H-2Kb–binding peptides Slc2a3 (VNTIFTVV), Nmt1
(AAYSFYNV), OVA, Stat3 (ATLVFHNL), and VSV were
loaded on RMA-S cells pretreated with trace NP68 agonist
peptide, we found that all peptides acted as strong coagonists
for F5 CD8+ T cells (Fig. 3, E and F).
A computational model of T cell activation
describes coagonism
Various computational and conceptual studies have dealt
with the principles behind coagonism (Li et al., 2004; Wylie
et al., 2007; Feinerman et al., 2008), but there has not yet
been a treatment that simultaneously incorporates the diffusion, binding, and reactions of proteins in space and time with
many available biophysical measurements. However, such kinetic models have been used to describe the different dependencies of T cell activation on CD4 and CD8 coreceptors
1809

Figure 2. Coagonism of OT-I and F5 CD8
T cells by both sc-H-2Kb and sc-H-2Db
nonstimulatory sc-MHCI. Inducible
sc-KbOVA or sc-DbNP68 CHO cells were supertransfected with constitutive sc-KbVSV or
sc-DbUTY and used as APCs to assess coagonism of OT-I and F5 T cells. CHO cell APCs were
stained for MHCI expression and in parallel
exposed to responder T cells whose activation
status was measured either by flow cytometry
or IL2 ELISA. Inducible sc-KbOVA APCs and OT-I
responder T cells are described in the top panels, whereas inducible sc-DbNP68 APC and F5
responder T cells are described in the bottom
panels. (A and E) Analysis of Kb or Db expression on CHO cell APCs. Color coding is as
shown in the y-axis labels of the bar graphs.
In A, sc-DbUTY-YFP fusion construct was used
to transfect cells expressing repressed KbOVA,
and the YFP fluorescence was used here to
report on sc-DbUTY expression relative to
untransfected CHO cells (black). In the remaining panels, sc-MHCI expression was
analyzed by antibody staining. (B and F)
OT-I (B) and F5 (F) CD8 T cell expression of
CD69 after incubation with the corresponding CHO APCs from A or E, respectively.
Horizontal black lines indicate the CD69hi
gate. (C and G) Bar graphs represent mean ±
SEM values of CD69hi cells for OT-I (C) and
F5 (G). (D and H) IL2 production after 8 h of
exposure to CHO cell APCs as indicated for
OT-I (D) and F5 (H). Statistical significance
(*, P < 0.05; **, P < 0.01; ***, P < 0.001) results
are from ANOVA analysis with Dunnett’s
post-test, referencing the repressed agonist
sample as the standard. For the OT-I CD69
bar graph in C, n = 8 (individual mice) after
removing outliers as defined by values >1.25
times the interquartile distance. For D, n = 4;
G, n = 6 (individual mice); H, n = 6. Each
data panel is representative of three independent experiments except C and G, which
report the combined results from three independent experiments.

(Artyomov et al., 2010).We applied this formalism to a description of coagonism, incorporating separate on and off rates for
TCR binding to agonist versus nonstimulatory pMHCI. The
OT-I TCR has approximately twofold higher affinity for agonist pMHCI than F5 (Kd of 5.9–6.5 μM for OT-I [Alam et al.,
1996, 1999] versus 11 μM for F5 [Willcox et al., 1999]). The
kinetics describing these equilibrium constants are markedly
different.The on and off rates for OT-I TCR–binding KbOVA
are well characterized (3,720/M/s and 0.022/s, respectively;
Alam et al., 1999). We calculated the on rate for the F5 TCR
for DbNP68 based on the off rate and equilibrium affinity
reported in the literature (koff = 0.8/s, Kd = 11 μM, kon =
72,727/M/s, calculated; Willcox et al., 1999). Therefore, we
varied the TCR kinetics for agonist pMHC in the kinetic
1810

model to be consistent with these binding data. The TCR on
rate for nonstimulatory peptides for both OT-I and F5 simulations was set to the OT-I value for KbOVA so that we could
directly compare nonstimulatory peptides with equal affinity
and kinetics. We developed this model (see Supplemental
text) that describes signal enhancement caused by the coexistence of agonist and nonstimulatory peptides on the APC
surface (Fig. 3 G). This model also describes increased TCR
signaling in response to nonstimulatory ligands with higher
CD8-binding affinities in both F5 and OT-I model systems
(Fig. 3 H). This computational result is consistent with the
following data: Fig. 2 showing a greater magnitude of enhancement by H-2Kb compared with H-2Db nonstimulatory
pMHC, Fig. 3 (B and D) showing the absolute dependence of
Coagonism and the role of CD8 affinity | Hoerter et al.
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Figure 3. The effect of CD8 affinity for coagonist pMHC on coagonism. Inducible sc-KbOVA
or sc-DbNP68 CHO cells were super-transfected
with constitutive sc-KbVSV CD8-binding mutant
(sc-KbVSV-CD8m) or sc-DbUTY CD8-binding mutant
(sc-DbUTY-CD8m), respectively, and used as APCs to
assess coagonism of OT-I and F5 T cells. CHO cell
APCs were stained for MHCI expression and in parallel exposed to responder T cells whose activation
status was measured by flow cytometry. (A) Anti-Kb
staining of CHO cells expressing sc-MHCI. Color coding as shown in B. (B) Percentage of CD69hi OT-I
T cells (from n = 10 individual mice) after 3-h exposure
to the CHO APCs in A. (C) Anti-Db staining of CHO
cells. Color coding as shown in D. (D) Percentage of
CD69hi F5 T cells (n = 6 individual mice) after 3-h
exposure to the CHO APCs in C. RMA-S cell were
also used as APCs to examine coagonism of F5
T cells. (E) Anti-Kb staining of RMA-S APCs loaded
with combinations of NP68 agonist peptide and
various H-2Kb–binding peptides: purple, Slc2a3;
orange, Nmt1; green, OVA; blue, Stat3; and red, VSV.
(F) Percentage of CD8+ F5 cells expressing CD69hi
after 3.5-h incubation with the RMA-S cells in E (n = 4).
A kinetic model of T cell activation reproduces the effect
of coagonism and describes a direct relationship
between CD8 affinity for coagonist pMHC and TCR
phosphorylation. (G) The kinetic model discriminates
based on antigen quality and exhibits enhanced TCR
phosphorylation (TCRpp) in the presence of nonstimulatory peptides. Results are shown for 10 agonist peptides alone and for 10 agonist plus 90
nonstimulatory peptides using OT-I kinetic parameters. (H) Results of computer simulations of the
kinetic model describing coagonism as a function of
CD8 affinity for nonstimulatory pMHC. Results are
shown for F5 and OT-I kinetic parameters. Statistical
significance (*, P < 0.05; ***, P < 0.001) results are
from ANOVA analysis with Dunnett’s post-test, referencing the repressed agonist sample (B and D) or the
sample with agonist alone (F) as the standard. Data in
A, C, E, and F are representative of three independent
experiments. Data in B and D are the combined results of three independent experiments. Error bars
represent SEM.

coagonism on CD8 binding to the nonstimulatory pMHCI,
and Fig. 3 F showing the lack of F5 coagonist peptide specificity for peptides bound to the high CD8-binding affinity
MHCI protein H-2Kb.
Minimal contribution of OT-I TCR recognition
of nonstimulatory pMHCI to coagonism
Previous studies showed no peptide dependence for coagonism by nonstimulatory pMHCI, with both OT-I preselection thymocytes and peripheral T cells (Yachi et al., 2005,
2007), nor was there any discrimination between endogenous
nonstimulatory peptides in signaling for negative selection by
covalent pMHC dimers containing one Kb-OVA with one
JEM Vol. 210, No. 9

nonstimulatory Kb ligand (Juang et al., 2010). To probe the
role of TCR interaction with the nonstimulatory ligands in
coagonism using the sc-MHCI system, we used several strategies. Residues in the A1A2-helices of MHCI comprise the
main recognition structures for TCR CDR1 and CDR2 (Sun
et al., 1995; Sim et al., 1998; Garcia et al., 2009). The E166K
mutation disrupts recognition of KbVSV by VSV-specific CTL
(Sun et al., 1995) and of KbOVA by OT-I CTL (not depicted).
Second, we used a chimera between the A1A2 domains of
the MHCIb molecule H-2TL (which cannot bind or present
peptide to TCRs; Devine et al., 2002; Weber et al., 2002;
Liu et al., 2003) and the A3 from H-2Kb, enabling normal
CD8 binding (Attinger et al., 2005). Both KbVSV with the
1811

E166K TCR-binding site mutation (sc-KbVSV-TCRm) and
the TL/Kb chimera provided significant coagonism for recognition of sc-KbOVA (Fig. 4, A and B), indicating that the
TCR interaction with nonstimulatory pMHCI was at most a
minor determinant of coagonism for OT-I T cells. We also
noted that recruitment of CD8AB to the immunological synapse (Yachi et al., 2005; Rybakin et al., 2011) was unperturbed by the sc-KbVSV-TCRm mutation (not depicted).
When we plotted CD69 expression data for OT-I T cells
versus MHCI expression on CHO cells for repressed and
induced sc-KbOVA, or repressed sc-KbOVA plus sc-KbVSV,
we found a linear relationship (Fig. 4 C). Repressed sc-KbOVA
plus sc-KbVSV-TCRm revealed a minor defect in coagonism
when TCR binding to nonstimulatory pMHC was attenuated. In contrast, the repressed sc-KbOVA plus the sc-KbVSVCD8m showed no coagonism.
A recent study showed that the OT-I TCR has a very
weak but biologically relevant interaction with endogenous
nonstimulatory ligands. Removal of this TCR interaction, for
example with a peptide designed to bind Kb but to lack TCR
interaction residues, abrogated coagonism (Juang et al., 2010).

To probe CD8 T cell coagonism with a similar strategy, RMA-S
cells were first loaded with a very small amount of OVA peptide followed by loading with a titration of peptides including
the OVA-derived antagonist/positively selecting peptide R4
(SIIRFEKL), the nonstimulatory peptide VSV (RGYVYQGL),
and the engineered peptide poly-serine (SSYSYSSL), which
should lack any TCR contact residues (Hogquist et al., 1994).
Each of these peptides acted as a coagonist in an H-2Kb expression–dependent manner (Fig. 4 D), indicating that for the
OT-I TCR, any discrimination based on the quality of the nonstimulatory peptide is at best very small.
Reduction in CD8-binding affinity for agonist pMHCI
enforces requirement for intact TCR interaction
with nonstimulatory pMHC
To test the impact of CD8 affinity for agonist pMHCI on coagonism, we tested sc-KbOVA-CD8m (Fig. 5, A and B). As
expected from previous work (Connolly et al., 1988, 1990;
Potter et al., 1989), this mutation minimized direct activation
of OT-I T cells by sc-KbOVA (Fig. 5 B and not depicted). Activation of OT-I T cells was rescued by sc-KbVSV but not by

Figure 4. Minor contribution of OT-I TCR binding to nonstimulatory pMHC in coagonism. Inducible sc-KbOVA CHO cells were super-transfected
with constitutive sc-KbVSV TCR-binding mutant (sc-KbVSV-TCRm) or H-2TL-KbA3 (TL/Kb) and used as APCs to assess coagonism of OT-I T cells. CHO cell
APCs were stained for MHCI expression and in parallel exposed to responder T cells whose activation status was measured by flow cytometry. (A) CHO cell
staining for either H-2Kb or H-2TL expression as indicated. Black indicates TL-negative staining control (Trex CHO cells). Other colors are as indicated in B.
(B) Percentage of CD69hi OT-I T cells (n = 10 mice) after 3-h exposure to the CHO APCs in A. (C) Percentage of CD69hi OT-I T cells plotted as a function of
the corresponding CHO APC H-2Kb expression, as indicated (n = 10 mice for CD69 data and n = 3 for H-2Kb expression on CHO cell APCs). A correction
factor of 2.8 is applied to the H-2Kb staining of the repressed KbOVA plus KbVSV-CD8m to account for attenuated anti-Kb staining resulting from the
CD8-binding site mutation (not depicted). RMA-S cell APCs were also used to test coagonism of OT-I T cells. (D) Percentage of CD69hi OT-I T cells plotted
as a function of Kb expression of RMA-S cells loaded with increasing concentrations of nonstimulatory peptides R4, VSV, and SSYSYSSL, as indicated
(n = 2 for both CD69 and H-2Kb expression). Statistical significance (*, P < 0.05; ***, P < 0.001) results are from ANOVA analysis with Dunnett’s post-test, referencing the repressed agonist sample as the standard. Data in A are representative of three independent experiments, and data in D are representative of
two independent experiments. Data in B and C are the combined results of three independent experiments. Error bars represent SEM (B and C) or SD (D).
1812
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sc-KbVSV-TCRm (Fig. 5 B). This was in stark contrast to
earlier results with repressed wild-type sc-KbOVA, in which
sc-KbVSV-TCRm was a strong coagonist (Fig. 4, B and C).
To further probe this discrepancy in coagonism by scKbVSV-TCRm, we took advantage of the fact that CD8 has
lower affinity for H-2Db than for H-2Kb (Moody et al., 2001b;
Huang et al., 2007). The CD8-binding affinity is a property
of the MHCI A3 domain, as a chimera of DbA1A2-KbA3

binds CD8 similarly to the native H-2Kb molecule (Moody
et al., 2001b). We therefore constructed and subsequently expressed inducible sc-KbOVA-DbA3 in CHO cells and supertransfected with sc-KbVSV or sc-KbVSV-TCRm.The altered
A3 domain epitope present in sc-KbOVA-DbA3 showed attenuated binding to the anti–H-2Kb antibody, visible in the
different anti–H-2Kb staining of the induced sc-KbOVA-DbA3
versus wild-type sc-KbOVA (Fig. 5 C).The amount of H-2Kb

Figure 5. Modulation of KbOVA CD8-binding affinity and associated changes in coagonism by KbVSV-TCRm. Inducible sc-KbOVA CD8-binding
mutant (sc-KbOVA-CD8m) CHO cells were super-transfected with constitutive sc-KbVSV or sc-KbVSV-TCRm and used as APCs to assess coagonism of
OT-I T cells. CHO cell APCs were stained for MHCI expression and in parallel exposed to responder T cells whose activation status was measured by
flow cytometry. (A) Anti-Kb stain of CHO cell APCs. Color coding is as shown in B. (B) Percentage of CD69hi OT-I T cells (n = 10 mice) in response to the
CHO cell APCs in A. Inducible domain-swapped sc-KbOVA-DbA3 CHO cells were also super-transfected with both sc-KbVSV or sc-KbVSV-TCRm and
used as APCs to assess coagonism of OT-I T cells. (C) Repressed and induced KbOVA (purple and green, respectively) and KbOVA-DbA3 (black and blue,
respectively) constructs were analyzed as a function of both OVA-Kb and total H-2Kb staining, whereas repressed KbOVA plus KbVSV-TCRm (red), repressed KbOVA-DbA3 plus KbVSV (orange), and repressed KbOVA-DbA3 plus KbVSV-TCRm (gray) were analyzed with H-2Kb staining alone. (D) CD69
expression of CD8+ OT-I T cells responding to the APCs described in C, with color coding as in C. The horizontal black line indicates the CD69hi
gate. (E) Percentage of CD69hi OT-I T cells (n = 4 mice) in response to the CHO cell APCs in C. (F) Calculated value of activation enhancement of
OT-I T cells plotted as a function of anti-Kb staining of the associated CHO APCs. Repressed KbOVA plus KbVSV-TCRm and repressed KbOVA-DbA3
plus KbVSV-TCRm are shown. Statistical significance (**, P < 0.01; ***, P < 0.001) results are from ANOVA analysis with Dunnett’s post-test, referencing the repressed agonist sample as the standard. Data in A are representative of three independent experiments. Data in B are the combined
results of three independent experiments. Data in C, D, and F are representative of two experiments, whereas the data in E are the combined results from two experiments. Error bars represent SEM (B and E) or SD (F).
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expression in the nonstimulatory sc-KbVSV and sc-KbVSVTCRm were comparable (Fig. 5 C).The CD69 expression profiles for OT-I CD8+ T cells (Fig. 5 D) and quantification of
CD69hi T cells (Fig. 5 E) clearly showed the lack of statistically
significant coagonism for sc-KbOVA-DbA3 plus sc-KbVSVTCRm compared with either of the significant responses found
for the sc-KbOVA-DbA3 plus wild-type sc-KbVSV or wildtype sc-KbOVA plus sc-KbVSV-TCRm.
Both repressed and induced sc-KbOVA-DbA3–expressing
CHO cells elicited systematically higher CD69 expression
than the wild-type sc-KbOVA in the responder OT-I T cells.
This result was unexpected, but we examined several different
clones of the inducible sc-KbOVA-DbA3 construct and each
one behaved in a similar manner (not depicted). This phenomenon could be explained by the serial TCR engagement
model (Valitutti, 2012), which proposes that a few agonist
pMHC complexes can initiate signaling from many TCRs.
Optimum induction of T cell activation occurs in response to
agonist pMHC complexes that engage TCR with intermediate
affinity, with half-lives sufficient to initiate productive TCR
ITAM phosphorylation but short enough to allow an individual pMHC molecule to serially trigger several TCRs. We
suggest that the attenuated CD8 affinity reduces the half-life
of OT-I/CD8 engagement by KbOVA-DbA3, bringing it
closer to the optimum values that allow more effective serial
TCR engagement and T cell activation. Because of this unexpected result, and to explicitly show the altered behavior
of sc-KbVSV-TCRm coagonists for the recognition of scKbOVA-DbA3 versus recognition of wild-type sc-KbOVA, we
calculated the activation enhancement of OT-I T cells (percent
CD69hi in response to repressed agonist with sc-KbVSV-TCRm
minus percent CD69hi in response to repressed agonist alone;
Fig. 5 F).This enabled comparison of coagonism by sc-KbVSVTCRm with these two different agonists, revealing that the
nonstimulatory ligand with reduced TCR interaction provided
greater coagonism for recognition of sc-KbOVA than for chimeric sc-KbOVA-DbA3. The results presented in Fig. 5 suggest that reduced CD8 affinity for antigenic pMHCI enforces
an increased reliance on TCR interaction with nonstimulatory
ligand to achieve coagonism.
Coagonist activity by H-2Db for F5 T cells requires
TCR discrimination of nonstimulatory pMHCs
The two antibodies used to stain sc-H-2Db–transfected CHO
cells in this study recognize different H-2Db epitopes. The
clone 27.11.13 recognizes a peptide-dependent conformational epitope, whereas the 28.14.8 clone recognizes the H-2Db
A3 domain independent of peptide (Fig. 6 A; Palmowski et al.,
2009). We prepared sc-DbGP33 and sc-DbGP33-TCRm
sc-MHC molecules, expressed them constitutively in CHO cells,
and stained with both 27.11.13 and 28.14.8 anti-Db antibodies.
These results show that the 27.11.13 antibody staining was
diminished by the TCR-binding site mutation on H-2Db
(Fig. 6 A). This offers strong evidence that the 27.11.13 antibody actually reports on the presence of amino acid residues
that are important for TCR recognition, both in the peptide
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sequence and MHC heavy chain.The sc-DbUTY clones used
in our assays stained strongly with 28.14.8 but relatively
weakly with 27.11.13 (Fig. 6 A). Linear regression analysis of
CD69hi F5 T cells after activation with repressed sc-DbNP68,
repressed sc-DbNP68 plus sc-DbUTY, or induced sc-DbNP68
revealed a very strong correlation between the percentage
of CD69hi T cells and 27.11.13 staining of the corresponding CHO cells (Fig. 6 B). No such correlation existed for
these same CD69 data plotted against 28.14.8 staining, suggesting that coagonism for the F5 TCR was sensitive to the
conformation of the A1A2 domains of the nonstimulatory
pMHC and/or to the peptide presented. This result suggested that there are fundamental differences in coagonism/
activation enhancement between the DbNP68-F5 and KbOVA–
OT-I systems.
To probe the question of the specificity of coagonism of
F5 T cells for nonstimulatory H-2Db pMHC, we screened
a small library of Y40 H-2Db–binding peptides (Table S1)
for H-2Db binding and the ability to act as coagonists for
F5 T cells when presented by RMA-S, identifying only two
variant influenza peptides as coagonists (not depicted). Neither
of these peptides (NP34, ASNENMETM; and NP371I,
ASNENIDTM) stimulates F5 T cells (Townsend et al.,
1986; Price et al., 2000), but NP34 can act as an antagonist
(Williams et al., 1998) and possibly so can NP371I (Price
et al., 2000). We therefore carefully tested these peptides for
direct activation of F5 T cells. RMA-S cells were loaded
with 100 μM each of NP34, NP371I, and PA224 (SSLENFRAYV, a Db-binding peptide which did not act as coagonist in our screen) or with 10 nM NP68 agonist peptide.
H-2Db was stabilized on RMA-S cells by binding of NP34,
NP371I, and PA224, but the H-2Db loaded with 10 nM
NP68 agonist was undetectable (Fig. 6 C). There was no
significant difference in T cell activation between salinetreated RMA-S cells and those presenting high amounts of
PA224, NP34, or NP371I on H-2Db (Fig. 6 D). RMA-S cells
treated with 10 nM NP68 peptide activated Y15% of F5 T cells.
To test for coagonism by PA224, NP34, and NP371I, we first
loaded RMA-S cells with 10 nM NP68 agonist, followed
by 100 μM each of PA224, NP34, and NP371I, as previously described (Yachi et al., 2007). After peptide loading,
these RMA-S cells expressed comparable amounts of H-2Db
(Fig. 6 E), and when used to stimulate F5 T cells, both
NP34 and NP371I, but not PA224, showed strong coagonist activity (Fig. 6 F).
Because of the positive coagonist results with sc-DbUTY–
expressing CHO cells, we also tested the ability of the UTY
peptide to support activation enhancement when presented
on RMA-S cells. UTY peptide loaded at 100 μM did stabilize H-2Db on RMA-S cells as measured by anti-Db staining
with antibody clone 28.14.8, but staining with the complementary anti-Db antibody 27.11.13 was negative for UTY
but positive for NP34 and PA224 (Fig. 6, G and H). The
fraction of F5 CD8+ T cells that up-regulated CD69 expression showed that the UTY peptide did not support activation
enhancement (Fig. 6 I).
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Figure 6. Contribution of F5 TCR recognition of nonstimulatory H-2Db pMHC to coagonism. Inducible sc-DbNP68 CHO cells were super-transfected
with constitutive sc-DbGP33, sc-DbGP33-TCRm, or sc-DbUTY and used either as APCs to assess coagonism of F5 T cells or as probes of anti-Db antibody specificity. (A) Dual anti-Db antibody staining (clones 28.14.8 and 27.11.13) of CHO cell APCs. (B) Percentage of CD69hi F5 T cells plotted separately versus the
27.11.13 and 28.14.8 anti-Db stains of corresponding CHO cell APCs in A. The black lines are linear fits to the data with the R2 value for the fit reported on the
graph (n = 6 mice). Error bars represent SEM. RMA-S cell APCs were also used to assess coagonism of F5 T cells by H-2Db–binding peptides. (C) Anti-Db staining of RMA-S APCs loaded with individual peptides. Gray shading shows RMA-S alone, and black shows RMA-S after 10 nM NP68 agonist addition. 100-μM
additions of peptides were as follows: blue, PA224; red, NP34; and green, NP371I. (D) Percentage of CD8+CD62L+CD44lo F5 cells expressing CD69hi after 3.5-h
incubation with the RMA-S APCs in C. (E) Anti-Db staining of RMA-S cells loaded with combinations of peptides to test coagonist activity, color coded as
indicated in C. (F) Percentage of CD8+CD62L+CD44lo F5 cells expressing CD69hi after 3.5-h incubation with the RMA-S cells in E. (G and H) Anti-Db antibody
staining with clones 27.11.13 (G) and 28.14.8 (H) of RMA-S cell APCs loaded with trace NP68 agonist with or without coagonists. Black indicates NP68 alone.
100 μM additions of peptides were as follows: blue, PA224; red, NP34; and green, UTY. (I) Percentage of CD8+ F5 cells expressing CD69hi after 3.5-h incubation
with the RMA-S cell APCs in G and H. Statistical significance (***, P < 0.001) results are from ANOVA analysis with Dunnett’s post-test, referencing the sample
with saline (D) or agonist alone (F and I) as the standard. Data in A are representative of three independent experiments, and data in B are the combined results from three independent experiments and are the same data as presented in Figs. 2 G and 3 D. For D and F, n = 5; for I, n = 15. For RMA-S assays with
NP34 and PA224, data are representative of six independent experiments, and for NP371I and UTY, data are representative of two independent experiments.
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Figure 7. Results of computer simulations of the kinetic model describing coagonism as a function of both TCR
affinity for nonstimulatory pMHC and
CD8 affinity for agonist pMHC. (A) Data
represent simulations for an OT-I–like TCR
affinity (modeled as kon, TCR for agonist =
3,720/M/s and koff, TCR for agonist = 0.02/s)
with 10 agonist and 90 nonstimulatory peptides. (B) Data represent simulations for an
F5-like TCR affinity (twofold lower affinity
than OT-I, modeled as kon, TCR for agonist =
72,727/M/s and koff, TCR for agonist = 0.8/s)
with 20 agonist and 80 endogenous peptides. $TCRpp enhancement values were
calculated from two different simulations for
each point on each curve. Symbols for different CD8 agonist MHC off rates are indicated, and the curves are color coded according to the TCRpp
value of the agonist plus nonstimulatory peptide simulations, where TCRpp values above the activation threshold of 10 (Artyomov et al., 2010) are red
and values below that threshold are blue.

Computer simulations reveal the importance
of TCR interaction with nonstimulatory pMHC
when CD8 binding to agonist pMHC is weak
To provide a mechanistic context to the experimental findings described here, that sensitivity of coagonism to the nature of the nonstimulatory peptide originates in part from
differences in CD8 affinity for agonist pMHCI, we modified
the computational model described above to introduce separate koff, CD8 values for agonist and nonstimulatory pMHC
species. This allowed us to systematically vary coreceptor
binding affinity to agonist pMHC while keeping coreceptor
binding to nonstimulatory pMHC constant.To test the different requirements of OT-I and F5 T cells for nonstimulatory
pMHC in responses to low amounts of their specific agonist
pMHCIs, we performed simulations with agonist peptides
only or with agonist plus nonstimulatory peptides.These simulations were performed over a range of high, intermediate,
and low CD8 affinities for agonist pMHC (koff, CD8 for agonist
pMHC of 50–300/s; Fig. 7 and not depicted; Cole et al.,
2012). Simulations were performed for relevant combinations
of parameters while varying the quality of the nonstimulatory
pMHC (koff,TCR for nonstimulatory pMHC ranging from 20/s
to 300/s). The results are presented as the increase in TCR/
CD3 phosphorylation $TCRpp,

ΔTCRpp = TCRppagonist , nonstimulatory − TCRppagonist only ,
and color coded according to the TCRpp value of the agonist
plus nonstimulatory peptide simulations, where TCRpp values >10 are considered activating (TCRpp denotes the mean
number of fully phosphorylated TCR; Artyomov et al., 2010).
The results revealed that for TCR with an OT-I–like agonist
affinity, coagonism showed little dependence on nonstimulatory pMHC quality for small values of koff, CD8 for agonist
pMHCI (i.e., high CD8 affinity; Fig. 7 A). With intermediate
or weak CD8 binding to agonist pMHCI, however, there was
stronger dependence on the quality of the nonstimulatory
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pMHC. At these weak CD8 agonist pMHCI–binding affinities, the lowest affinity nonstimulatory peptides provided
little signal enhancement, and the absolute TCRpp value
for these simulations fell below the activation threshold of
TCRpp = 10. For the TCR with F5-like affinity for agonist
pMHC (Fig. 7 B), there was a steeper dependence on nonstimulatory pMHC–TCR off rate at low koff, CD8 (high CD8
affinity) for agonist pMHC. This indicates that the kinetics of
the TCR–agonist pMHCI interaction play a role in the requirement for specific coagonists. However, at the smallest
values of koff, CD8 for agonist pMHC, coagonism of F5 was still
significant and the absolute values of TCRpp for the simulations of agonist plus nonstimulatory peptides remained above
the threshold of 10. For intermediate koff, CD8 for agonist
pMHC, only the highest affinity nonstimulatory peptides
gave any appreciable activation. At the highest values of koff,
CD8 for agonist pMHC, the nonstimulatory pMHC gave no
coagonism for F5.These computational results provide a conceptual framework describing our experimental results, in
which we found that CD8 affinity for agonist pMHCI is a
key factor for the dependence of coagonism on the TCR’s
interaction with the nonstimulatory pMHC.
DISCUSSION
Recent work has demonstrated that nonstimulatory peptides
bound to MHC can enhance T cell recognition (Krogsgaard
et al., 2005; Yachi et al., 2005, 2007; Anikeeva et al., 2006;
Davis et al., 2007; Gascoigne, 2008; Gascoigne et al., 2010;
Juang et al., 2010).To investigate the parameters of the coagonist phenomenon for CD8 T cells, we developed a system
where very low expression of sc-pMHCI agonists for specific
TCRs was coupled with constitutive expression of nonstimulatory sc-pMHCI. Using OT-I and F5 TCRs, we tested
combinations of H-2Kb and H-2Db, as well as mutations in
the cognate or nonstimulatory MHC, to identify the interactions important in coagonism. In addition, we used computer
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simulations of T cell activation to verify our key conclusions
and develop a conceptual model.
Our results describe two distinct mechanisms for which
coreceptor binding to pMHC influences the phenomenon of
coagonism. In the first and most obvious mechanism, we find
that CD8 affinity for the nonstimulatory pMHC exerts several effects on coagonism. We found that both H-2Db and
H-2Kb molecules supported coagonism but that activation
enhancement by nonstimulatory Db ligands was less effective
than Kb ligands for both (Kb restricted) OT-I and (Db restricted) F5 T cells. This demonstrated that the phenomenon
of coagonism is not restricted to a single MHCI molecule
and suggested that coagonism correlated with the CD8 binding affinity for nonstimulatory MHC, as CD8 affinity for
H-2Kb is stronger than for H-2Db (Moody et al., 2001b;
Huang et al., 2007; Cole et al., 2012). In addition, when coagonist peptides were presented to F5 on H-2Kb with RMA-S
cell APC, we found that the higher CD8 affinity for the nonstimulatory Kb enabled coagonism to occur for all the peptides
tested. To provide a conceptual framework within which to
test our experimental results, we modified a kinetic model of
T cell activation (Artyomov et al., 2010) to include nonstimulatory pMHC. In stochastic computer simulations, we systematically varied the affinity of CD8 for pMHC. The results
showed that coagonism depends on the affinity of CD8 for
nonstimulatory pMHC, rendering our model consistent with
experimental findings showing that higher CD8 affinity for
nonstimulatory H-2Kb gives stronger coagonism than does the
lower CD8 affinity for H-2Db.
The direct correlation between CD8 affinity for nonstimulatory pMHC and the magnitude of coagonism suggested
that CD8 binding to nonstimulatory pMHC is a dominant
factor in coagonism. By introducing CD8-binding site mutations (CD8m) in the A3 domains of sc-KbVSV and sc-DbUTY,
we found that CD8 binding to nonstimulatory pMHC is an
absolute requirement for coagonism. In the F5 system, the scDbUTY-CD8m actually manifested a statistically significant
inhibition of activation, which we interpret as competitive
inhibition, similar to the finding that coagonist pMHCs become antagonists in the absence of CD8 (Stone et al., 2011).
The requirements for the interaction of TCR with the
nonstimulatory pMHC for coagonism are complex. For OT-I
T cells recognizing sc-KbOVA, we detected a very mild coagonist defect using sc-KbVSV-TCRm as nonstimulatory pMHC.
This defect was only clear when we accounted quantitatively
for T cell activation as a function of total MHC expression on
the APCs. The minimal contribution of the affinity of OT-I
TCR for nonstimulatory pMHC to coagonism was confirmed
by two other findings. First, the TL/Kb chimera that cannot
bind peptide significantly enhanced activation of OT-I T cells
and, second, that a peptide designed to have no TCR interaction
(poly-serine; Hogquist et al., 1994) was an effective coagonist,
similar to other nonstimulatory peptide–Kb complexes.
This complete lack of specific coagonism for OT-I T cells
is a convolution of the relatively strong CD8 binding to
nonstimulatory H-2Kb pMHC, mechanism 1 described above,
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and a second mechanism involving the affinity of CD8 for
agonist pMHC, consistent with the experimental data described hereafter and described by the kinetic model used
in our study. By testing a gradient of CD8 affinities for the
agonist sc-KbOVA, using sc-KbOVA-DbA3 chimera and CD8m
constructs, we found that the requirement for TCR recognition of the nonstimulatory sc-KbVSV became more stringent
as the ability of CD8 to bind agonist sc-KbOVA was reduced.
sc-KbVSV-TCRm gave slightly reduced coagonism compared
with wild-type sc-KbVSV for agonist sc-KbOVA stimulation,
but sc-KbVSV-TCRm coagonism for sc-KbOVA-DbA3 agonist was significantly reduced. sc-KbVSV-TCRm was unable
to provide coagonism for sc-KbOVA-CD8m. Thus, loss of
CD8 binding to sc-KbOVA introduced an absolute requirement for the OT-I TCR to bind to the nonstimulatory pMHC
to drive activation, whereas weak CD8 binding to agonist revealed a partial requirement for TCR recognition of the nonstimulatory ligand.
Using the H-2Db–restricted F5 TCR and correlations
with two different anti–H-2Db antibody–mediated measures
of CHO H-2Db expression, the associations that we uncovered suggested that coagonism of F5 cells by sc-DbUTY nonstimulatory pMHC was dependent on the TCR interaction
with nonstimulatory H-2Db. This requirement for TCR
discrimination of the nonstimulatory pMHC suggests that
coagonism for F5 recognition of DbNP68 should be more
peptide specific than OT-I recognition of KbOVA. To further
probe the question of peptide-specific coagonism of F5 T cells
by nonstimulatory peptides bound to H-2Db, we used the
RMA-S cell APC system. From a library of Y40 peptides, we
found only two H-2Db–binding peptides that acted as coagonists for F5 T cells. Both of these peptides were variant influenza peptides, each differing in only two amino acid residues
from the NP68 agonist. These data show that coagonism for
F5 T cells requires TCR binding to nonstimulatory pMHC,
where only peptides closely related to the antigen worked as
coagonists. In contrast, as described above, when nonstimulatory peptides are presented to F5 T cells on H-2Kb (along
with agonist NP68 on H-2Db), the peptide specificity of coagonism is lost because of the increased CD8 affinity of the
coagonist H-2Kb pMHC (i.e., mechanism 1).
We tested the ability of the UTY peptide bound to RMA-S
to act as a coagonist for F5 T cells. As shown in Fig. 6 I, the
UTY peptide did not support activation enhancement of F5
T cells when presented on RMA-S cells. However, sc-DbUTY
expressed on CHO cells did give some degree of F5 coagonism.We can offer two potential explanations for this discrepancy. It is possible that coagonism by sc-DbUTY results from
the relatively high H-2Db expression on CHO compared
with RMA-S (Fig. 6, compare A and B with G and H, for
example) or is an artifact supplied by the single-chain design,
for example by the presence of the stabilizing linker between
the peptide and B2m. However, based on the 27.11.13 and
28.14.8 anti-Db antibody correlation analysis of sc-UTY
(Fig. 6, A and B), we concluded that an observable anti-Db
27.11.13 antibody stain correlated with activation enhancement
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by the UTY peptide (Fig. 6 B). Consistent with this requirement, we found that H-2Db bound to UTY peptide on
RMA-S cells did not stain with the 27.11.13 antibody but
did stain with the 28.14.8 antibody (Fig. 6, G and H). Therefore, based on the lack of 27.11.13 staining of RMA-S cells
loaded with UTY peptide, we would not predict UTY to act
as a coagonist.
The picture of mechanism 2 that emerges from the kinetic model is one in which activation of Lck upon TCR
binding to agonist pMHC (Stirnweiss et al., 2013) is followed
by this active Lck–CD8 complex finding other TCR–pMHC
complexes in the vicinity on the cell membrane.This Lck can
phosphorylate even short-lived complexes of TCR with nonstimulatory pMHC that may be nearby. The kinetic model
validated in this study suggests that agonists presented by
MHCI with high affinity for CD8 promote a higher likelihood (or effective concentration) of CD8 complexes with
active Lck than do agonists presented by MHC molecules
with low CD8 affinity. For coagonism to occur for weakly
CD8-binding agonist pMHC, a longer half-life of the ternary
TCR–nonstimulatory pMHC–CD8 complex is required
because of the lower amount of active Lck. This increase in
stability can be achieved with either a higher-affinity TCR–
nonstimulatory pMHC interaction or a higher-affinity CD8–
nonstimulatory pMHC interaction (i.e., mechanism 1).
Thus, the overarching principle that emerges from our
study and from the literature is the relationship between coreceptor affinity for pMHC and the peptide specificity of
T cell activation. CD8 affinity for agonist pMHC plays a direct role in signaling through the TCR, where increasing the
affinity of CD8 increases ligand potency and the number
of peptides recognized as agonists, and can even bypass peptide specificity requirements altogether (Laugel et al., 2007;
Wooldridge et al., 2007, 2010). In addition to greater crossreactivity, increased CD8 affinity will make a larger proportion of nonstimulatory ligands potential coagonists through
both mechanisms described here. Collectively, these data
therefore suggest that the highest peptide specificity of T cell
activation is achieved with MHC molecules with the lowest
affinities for coreceptor.
Our results provide a unifying view of coagonism as these
conclusions are also applicable to CD4 T cells, in which CD4
affinity for MHCII is lower than CD8 affinities for MHCI
(van der Merwe and Davis, 2003). The lower-affinity H-2Db
MHCI agonists behave more like the previously characterized CD4 T cell systems, where only a very restricted set of
coagonist peptides can support enhancement. Previously proposed qualitative and mathematical models of coagonism
studied in the context of CD4 T cells are closely related to the
model we have studied here (Li et al., 2004; Krogsgaard et al.,
2005). These earlier calculations were modeled in the “wellmixed” limit and did not explicitly study the mechanism by
which active Lck coreceptor created by agonist pMHC–TCR
complexes “found” the vicinal endogenous pMHC–TCR complexes and interacted with them via the coreceptor. Here, among
other extensions, we have explicitly included considerations
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of protein mobility and modeled the relative motion of integral membrane proteins. The work presented here not only
reveals a consistent set of requirements for CD8 and TCRbinding affinities to the disease-related agonist and the self–
nonstimulatory pMHC complexes, but also allows us to
formulate predictions about coagonism for systems in which
it has not yet been systematically investigated and suggests
explanations for some enigmatic reports in the literature.
Mouse CD8 affinity for MHC is higher on developing thymocytes than on mature CD8+ T cells (Daniels et al., 2001;
Moody et al., 2001a), and we predict that a larger set of peptides will be coagonists for thymocytes than for peripheral
CD8+ T cells, especially for T cells bearing Db-restricted
TCR. In addition, a study of LCMV CTL responses showed
that H-2Db–restricted CTL numbers were decreased in H-2Kb
knockout mice (Kotturi et al., 2008), a result which is likely
caused by the action of mechanism 1 as described in this study,
on both positive selection and coagonism of H-2Db–restricted
CTL by H-2Kb–bound coagonists. More importantly, human
CD8 affinity for HLA is generally lower than that of mouse
CD8 for H-2 MHCI molecules (Cole et al., 2012), so we predict that during human CD8 T cell activation, only a restricted
set of nonstimulatory peptides will support activation enhancement, similar to mouse CD4+ and Db-restricted CD8+
T cells. Moreover, several HLA alleles confer human disease
susceptibility or protection, and the work presented here suggests that different coagonism potentials of distinct MHCI
alleles could contribute to this association.
MATERIALS AND METHODS
Plasmids. Single-chain trimer MHC KbOVA and DbNP68 (Choudhuri
et al., 2005; Palmowski et al., 2009) were cloned into the pcDNA5/TO vector (hygromycin resistance; Invitrogen) for inducible expression of agonist.
KbVSV (Yu et al., 2002) and the TL/Kb chimera (Attinger et al., 2005) were
used in the pcDNA3.1 vector. Constitutive expression of DbNP68, DbUTY,
DbUTY-YFP fusion, and DbGP33 was from the pKG4 vector backbone.
D227K-E229K CD8-binding mutations (“CD8m”) and the E166K TCRbinding mutation (“TCRm”) were introduced by site-directed mutagenesis.
The A3 domain–swapped construct was made by overlap PCR. All constructs were prepared by Maxiprep (QIAGEN) before transfection.
Antibodies. CD8A (53-6.7), CD3d (145-2C11),VA2 (B20.1), CD44 (IM7),
CD62L (MEL-14), CD69 (H1.2F3), OVA-Kb (25.D1.16), H-2Kb (AF6-88.5),
H-2Db (27.11.13), and H-2Db (28.14.18) were obtained from BD, eBioscience, BioLegend, or Abcam. Anti–H-2TL (18/20) was a gift of C. Lena and
H. Cheroutre (La Jolla Institute for Allergy and Immunology, La Jolla, CA).
Mice. OT-I, OT-I Rag1/, and F5 Rag1/ mice, all on the B6 background
(at least 10 backcross generations), were bred at the Scripps Research Institute (TSRI). F5 mice were provided by K. Walsh and M. Oldstone (TSRI).
Protocols were approved by the Institutional Animal Care and Use Committee of TSRI.
Peptides. OVA (SIINFEKL),VSV (RGYVYQGL), UTY (WMHHNMDLI),
and NP371I (ASNENIDTM) were obtained from Peptides International; R4
(SIIRFEKL), poly-serine (SSYSYSSL), and NP68 (ASNENMDAM) were obtained from the Scripps Peptide Core Facility; and NP34 (ASNENMETM),
PA224 (SSLENFRAYV), and several other H-2Db–binding peptides (Table S1)
were provided by J. Sidney and A. Sette (La Jolla Institute for Allergy and Immunology) or D. Popkin (TSRI). Slc2a3 (VNTFTVV), Nmt1 (AAYSFYNV),
Coagonism and the role of CD8 affinity | Hoerter et al.

Ar ticle

and Stat3 (ATLVFHNL) were provided by S. Jameson (University of
Minnesota, Minneapolis, MN).
CHO cell culture, transfection, and cloning. CHO cells expressing the
tetracycline repressor (Trex; Invitrogen) under blasticidin selection (10 μg/ml)
were grown in Ham’s F12 media with 10% (vol/vol) FCS, 100 U/ml penicillin, and 10 mg/ml streptomycin. CHO cells were passaged with trypsin.
Transfection of CHO cells was accomplished with FuGENE 6 (Roche)
transfection reagent, and the cells were subsequently drug selected (0.3 mg/ml
hygromycin and 0.8 mg/ml G418), cloned by limiting dilution, and screened
for MHC transgene expression by FACS. To prepare for a T cell activation
experiment, CHO cells were trypsinized, counted using a Beckman Coulter
Z1 particle counter, and plated overnight at 20,000 cells per well of a 96-well
plate for T cell activation or 200,000 cells per well of a 12-well plate for separate MHC staining. CHO cells were scraped for MHC staining analysis.
Doxycycline was added to a final concentration of 50 ng/ml for induction of
agonist expression.
RMA-S cell peptide loading. RMA-S cells were maintained in serumfree Aim V media (Invitrogen).The afternoon before an experiment, RMA-S
cells near confluence were washed, diluted to 106 cells/ml in Aim V media,
and plated at 28°C overnight.The next morning, dilute agonist peptide (100 pM
OVA or 10 nM for NP68) was added to the cells and incubated for 30 min
at 28°C. The cells were washed with Aim V media, counted, diluted to 106
cells/ml in Aim V media, and plated at 100,000 cells per well of replica 96well plates. RMA-S cells incubated overnight at 28°C but without agonist
peptide were plated for controls. Nonstimulatory peptides were added to the
RMA-S cells over a final concentration range of 107 to 104 M, mixed well,
and incubated for another 30 min at 28°C. The cells were then washed and
resuspended in 100 μl of fresh Aim V media. The cells were then shifted to
37°C, where after 3 h they were ready for the assay. One plate was used for
RMA-S MHC staining and one plate used for T cell activation.
T cell activation assays. Lymphocytes were extracted from the TCR
transgenic mice and incubated as single-cell suspensions in cRPMI (RPMI
medium supplemented with 10% [vol/vol] FCS, 100 U/ml penicillin, 10 mg/ml
streptomycin, 292 mg/ml glutamine, 50 mM 2-mercaptoehthanol, and 25 mM
Hepes, pH 7.3) for 1–3 h at 37°C. Lymphocyte suspensions were diluted to
2–2.5 × 106 cells/ml for OT-I cells and 1–1.5 × 106 cells/ml for F5 Rag1/
cells. 100 μl of the lymphocyte suspension was added per well of the 96-well
plate for CHO and RMA-S activation assays, mixed, allowed to interact at
37°C for the allotted time (typically 3–4 h), chilled on ice, and stained for
FACS analysis of activation. For assays of IL-2 in the supernatant, plates were
spun at the designated stopping point, and the supernatant was removed and
frozen for later analysis by IL-2 ELISA (EMD Millipore).
Flow cytometry. All flow cytometry was conducted on BD LSR-II cytometers at the Scripps Research Flow Cytometry Core Facility. Flow cytometry
data were analyzed in FlowJo (Tree Star) and exported where necessary.
Statistical analysis. Data analysis was performed in Excel (Microsoft) and
Igor Pro (WaveMetrics). All indications of statistical significance stem from
p-values derived from ANOVA analysis with Dunnett’s post-test as implemented in Igor Pro.
Online supplemental material. Table S1 lists the library of peptides tested
in RMA-S cell assays. The supplemental text includes SSC code, rate parameters, and a list of chemical species for the computer simulations of the kinetic model. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20122528/DC1.
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